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microRNAs (miRNAs) are a novel class of non-coding RNAs which found their way into
the clinic due to their fundamental roles in cellular processes such as differentiation,
proliferation, and apoptosis. Recently, miRNAs have been known as micromodulators
in cellular communications being involved in cell signaling and microenvironment
remodeling. In this review, we will focus on the role of miRNAs in cardiovascular diseases
(CVDs) and their reliability as diagnostic and therapeutic biomarkers in these conditions.
CVDs comprise a variety of blood vessels and heart disorders with a high rate of
morbidity and mortality worldwide. This necessitates introduction of novel molecular
biomarkers for early detection, prevention, or treatment of these diseases. miRNAs, due
to their stability, tissue-specific expression pattern and secretion to the corresponding
body fluids, are attractive targets for cardiovascular-associated therapeutics. Explaining
the challenges ahead of miRNA-based therapies, we will discuss the exosomes as
delivery packages for miRNA drugs and promising novel strategies for the future
of miRNA-based therapeutics. These approaches provide insights to the future of
personalized medicine for the treatment of CVDs.
Keywords: miRNA, cardiovascular disease, cardio-miR, exosome, cell communication, delivery vehicle, secretory
miRNA, miRNA therapeutics
Introduction
Among multifactorial diseases, cardiovascular diseases (CVDs) are signiﬁcant due to their variable
symptoms and high mortality rate accounting for one third of global deaths (Santulli, 2013). They
include a wide range of disorders connected to blood vessels and heart ranging from coronary
artery disease (CAD), pulmonary arterial hypertension (PAH), and congenital heart disease to
deep vein thrombosis and cerebrovascular disease. Major CVD risk factors include family history,
obesity, hypertension, diabetes mellitus, and hypercholesterolemia (Mendis et al., 2011). Since
CVDs are hard-to-cure, several investigations have focused on diﬀerent mechanisms underlying
CVD in order to manage the symptoms. microRNAs have emerged as one of the most favorable
molecular targets in this regard. microRNAs are a class of non-coding RNAs with a short length
of 18–24 nucleotides. They mainly act as post-translational repressors of gene expression. By
regulating the fundamental cellular mechanisms such as cell diﬀerentiation, proliferation, growth,
and apoptosis, miRNAs have received enormous attention for therapeutic applications. Huge
investigations and investments have been made to bring these molecules into the clinic. In this
review, we will explain the novel diagnostic, therapeutic and prognostic approaches based on
miRNAs in the ﬁeld of CVDs (cardio-miRs) and the problems ahead of this research area; where
we are and where we expect to be in the future.
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miRNA Mechanisms of Action
Calin et al. (2002) were ﬁrst to link miRNAs with cancer
progression. Since then several studies have focused on the
role of these small molecules in the pathogenesis of diﬀerent
human diseases. The primary ﬁndings emphasized on the post-
transcriptional regulatory role of miRNAs through base pairing
with the 3′ untranslated region (UTR) of their target mRNAs.
This leads to the mRNAdegradation or translation inhibition and
in both cases the miRNA binding results in the suppression of
their target mRNAs. This is the main mechanism reported for the
miRNAs regulatory role; however, many variations have also been
reported (Ha and Kim, 2014; Lin and Gregory, 2015). miRNA
binding to the 5′ UTR of transcripts has also been demonstrated
to be able to activate or suppress target genes (Lee et al., 2009).
Some miRNAs can also bind to the open reading frame (ORF)
of mRNA transcripts and repress translation. This mechanism
was ﬁrst reported by Tay et al. (2008). They demonstrated that
miRNA binding to the coding region of pluripotency genes
can regulate the embryonic stem cell diﬀerentiation. miRNA
binding might also happen at the promoter of target gene
which causes repression of gene translation. On the other hand,
some miRNAs modulate their target expression by binding to
RNA-binding proteins that regulate the expression of mRNA
transcripts (Eiring et al., 2010). Salmena et al. (2011) proposed
the competing endogenous RNA (ceRNA) hypothesis according
to which, miRNAs, long non-coding RNAs (lncRNAs) and
target mRNAs are in a ﬁnely tuned interaction through miRNA
response elements (MREs) and their competition for target
binding based on their total concentration in the cytoplasm
deﬁnes a higher level of regulation. Recent studies have indicated
another fascinating aspect of miRNA regulatory network. Fabbri
et al. (2012) proved that miRNAs excreted from cancer cells,
can directly bind the toll-like receptors (TLRs) at the surface
of neighboring immune cells and activate the relevant signaling
pathways in the recipient cells. The complexity of miRNA-
mediated regulatory systems highlights the importance of these
small molecules in the clinic and needs further proceeding
technologies to get closer to clinical therapies.
miRNA Diagnostics in CVD
microRNAs show tissue-speciﬁc and time-dependent expression
patterns turning them into a leading fact in using these
small molecules as diagnostic and therapeutic targets (Lu
et al., 2005). Similar to other developmental phenomena in
embryogenesis, miRNAs play critical roles in cardiovascular
development and also their expression proﬁle changes
according to diﬀerent pathological conditions. Cardiac
resynchronization therapy (CRT) after heart failure helps
improve the heart arrhythmia and it also aﬀects the myocardial
miRNA expression. In responder patients, CRT aﬀects cardiac
processes including cardiac ﬁbrosis, apoptosis, angiogenesis,
and channel alterations and consequently alters the expression
levels of miR-29 (implicated in cardiac ﬁbrosis), miR-30,
miR-92, and miR-145 (involved with cardiac angiogenesis),
miR-30 (modulated in cardiac apoptosis), and miR-26
(aﬀected by modiﬁed ionic channel function; Sardu et al.,
2014).
Recently circulatory miRNA expression proﬁling has provided
strong molecular markers for detection of various diseases
including CVD such as myocardial hyperthrophy, infarction,
angiogenesis and ﬁbrosis (Charan Reddy, 2014; Wronska
et al., 2015). van Rooij et al. (2006) deﬁned a miRNA
signature for cardiac hypertrophy. They showed that miR-
195 overexpression is suﬃcient to drive cardiac hypertrophy.
miR-1 family, miR-133a/b and miR-208 are well-known for
their implication in myogenesis both in skeletal muscles and
cardiac development and their dysregulation has been detected
in several CVDs including myocardial infarction, hypertrophy,
and arrhythmias (Thum et al., 2008a). While miR-208 showed
signiﬁcant upregulation (pro-hypertrophic), miR-1 and miR-
133a expression levels signiﬁcantly decreased (anti-hypertrophic)
in acute myocardial infarction (AMI) compared with normal
individuals heart (Bostjancic et al., 2010). In CAD, miR-1 is
upregulated in the left ventricular endocardium (Yang et al.,
2007) and also plasma levels of miR-1, miR-133, and miR-
208b have been reported to be elevated after AMI (Widera
et al., 2011; Devaux et al., 2015). However, the circulatory miR-
1 is not sensitive or speciﬁc enough to be known as an AMI
speciﬁc biomarker since it is also aﬀected by factors other than
AMI. Moreover, by targeting Protein phosphatase 2A regulatory
subunit B56 alpha (PP2A), miR-1 has been linked to the
arrhythmia mainly through hyperphosphorylation of ryanodine
receptor (RyR2; Terentyev et al., 2009). Following hypertension
or cardiac infarction, cardiac hyperthrophy, and cardiac ﬁbrosis
are common diseases in which the excess amounts of extracellular
matrix (ECM) proteins accumulate in cardiac tissue in order to
adapt the system to the pathological conditions. Overexpression
of miR-29 and miR-21 and downregulation of miR-133 and
miR-30 have been linked to ECM remodeling and ﬁbrosis by
regulating several components of the ECM including collagen
type I alpha 1 and 2 (Col1A1 and Col1A2) as targets of miR-
29 (van Rooij et al., 2008), sprouty homolog 1 (SPRY1) as a
target of miR-21 (Thum et al., 2008b) and connective tissue
growth factor (CTGF) as target of miR-133 andmiR-30c (Duisters
et al., 2009). miR-133 is speciﬁcally expressed in cardiomyocytes
while miR-30 is also detectable in cardiac ﬁbroblasts as well as
cardiomyocytes. These and other miRNAs (including miR-328)
have been linked to atrial ﬁbrillation which is mainly resulted
from structural remodeling and ﬁbrosis (Santulli et al., 2014a).
Table 1 summarizes a list of miRNAs involved in diﬀerent CVDs
(cardio-miRs).
miRNA-Bearing Exosomes as
Communicators of CVD
Recent miRNA-based studies have focused on the role of
exosomes as natural delivery vehicles for some proteins, mRNA,
and miRNAs which facilitate communication between cells
and their neighboring stroma. Exosomes are small vesicles
(40–100 nm) originating from the plasma membrane or
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TABLE 1 | List of cardio-miRs involved with different cardiovascular disorders.
miRNA name Diseases name Detection approach Dysregulation Reference
miR-208a/b, miR-499 AMI and myocardial injury Microarray and real-time PCR Upregulation in the plasma of patients Corsten et al. (2010),
Wang et al. (2010)
miR423-5p Heart failure Microarray and real-time PCR Upregulation in the plasma of patients Tijsen et al. (2010)
miR-328 Atrial fibrillation (adverse
electrical remodeling)
Microarray and real-time PCR Upregulation in left atrial samples (from
dogs)
Lu et al. (2010)
miR-1 AMI Real-time PCR Upregulation in the patients’ serum Cheng et al. (2010)
miR-26a Cardiovascular repair;
acute coronary syndromes
Real-time PCR Upregulation in the Patients’ plasma Icli et al. (2013)
miR-16, miR-27a, miR-101, and
miR-150
Left ventricular contractility
(LV)
Real-time PCR Downregulation of miR-101 or miR-150
and upregulation of miR-16 or miR-27a
correlate with higher risk of impaired LV
contractility
Devaux et al. (2013)
miR-133a AMI and coronary artery
stenosis
Real-time PCR Upregulation in the Patients’ plasma Wang et al. (2013)
miR-126, miR-17/miR-92a,
miR-155
Coronary artery disease Microarray and real-time PCR Reduction in serum and plasma of
patients
Fichtlscherer et al.
(2010)
miR-126 Congestive heart failure; Real-time PCR Negative correlation with NYHA class;
downregulation in patients; positive
association with incident MI
Fukushima et al. (2011)
miR-126 Myocardial infarction (MI) Real-time PCR Upregulation in plasma samples of MI
patients; positive association with MI
incidence
Zampetaki et al. (2012)
miR-1, miR-134, miR-186,
miR-208, miR-223, and miR-499
AMI and angina pectoris Deep sequencing Upregulation in serum samples of AP
patients compared to AMI
Li et al. (2013)
miR-106b/25 cluster,
miR-21/590-5p family, miR-126∗ ,
miR-451
Coronary artery disease Microarray and real-time PCR upregulation in plasma of patients with
unstable angina
Ren et al. (2013)
AMI, acute myocardial infarction; AP, angina pectoris; NYHA, New York Heart Association.
multivesicular bodies (MVBs) and are present in almost all
biological ﬂuids. They shuttle between neighboring cells and
transfer their cargoes which can be cellular components including
proteins, mRNA, and non-coding RNAs. These cargoes can
perform regulatory eﬀects and control gene expression in the
recipient cells (Pegtel et al., 2010). Exosomes are famous for being
the communicators of microenvironment. Exosomal membrane
proteins as well as other components are usually similar to their
originating cell. Their membranes usually contain higher levels
of sphingomyelin, cholesterol and phosphatidylserine compared
to their originating cells. Their cargo also might represent the
cellular composition of RNAs and proteins or they might show
a separate proﬁle. Methodologies including immunoblotting,
aﬃnity extraction into magnetic beads and ﬂow cytometry have
been used to identify the protein components of exosomes.
Proﬁling of RNAs – miRNAs in particular – is usually performed
by means of microarrays, qPCR-based arrays and most recently
by next generation sequencing techniques which analyze the
transcriptome – miRnome – of each sample.
Recent studies have proved targeted packaging of miRNAs
and their biogenesis components including Dicer and AGO2 in
exosomes (Melo et al., 2014). Exosome shuttling is implicated in
a variety of disease including cancer, CVDs or viral infections. In
CVD, exosomal transfer of miRNAs is a well-known mechanism
through which, cells educate their adjacent environment in order
to confront the pathological condition. In heart ischemia or
ﬁbrosis, paracrine or endocrine secretion of miRNA-bearing
exosomes into cardiomyocytes or active ﬁbroblasts of the heart
have been demonstrated. This leads to trans-diﬀerentiation
of ﬁbroblasts into an active state with a diﬀerent rate of
growth factors secretion (van Rooij and Olson, 2009; Yoo
et al., 2011). Bang et al. (2014) proved that following heart
infarction, exosome-secretion from cardiomyocytes with a new
miRNA proﬁle, can reprogram the cardiac ﬁbroblasts leading to
cardiac hypertrophy. These mechanisms can introduce potential
novel therapeutic targets. As well, recognizing tissue-speciﬁc
CAF markers, the mechanisms underlying their reactivation
and the miRNA signals in these processes, will potentially
provide promising targets for CVD therapies. In addition to
the ﬁbroblasts in the microenvironment, exosomal transfer of
signals is also used for cardiovascular protection after a disease.
For example in heart ischemia, secretory exosomes with miRNA
cargos from cardiomyocytes have been shown to activate and
induce the bone marrow-derived stem cells. These latter cells
release the second subset of exosomes that lead to myocardial
regeneration or protection (Sahoo and Losordo, 2014). Several
investigations have demonstrated the selective packaging of
miRNAs in exosomes and their secretion to the stroma of cells by
means of signal molecules. This is beyond shedding the vesicles
by plasma membrane (Yang et al., 2011; Montecalvo et al., 2012;
Stoorvogel, 2012). These disease-speciﬁc expression patterns of
exosomal miRNAs – which can be non-invasively detected in
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the body ﬂuids – provides potential molecular markers and
promising therapeutic targets for treatment of CVDs. Several
circulating miRNAs have been linked to some CVDs. In patients
with AMI and myocardial injury, higher levels of miR-208a have
been detected in the plasma of patients and they showed higher
speciﬁcity and sensitivity than conventional biomarkers such as
cardiac troponin I (TnI) for diagnosis of the disease (Ji et al.,
2009; Wang et al., 2010). Another potential biomarker for AMI
is reported by Adachi et al. (2010) who detected higher plasma
levels of miR-499 in patients with AMI compared with normal
individuals. Using microarray analysis of exosomes obtained
from cardiac progenitor cells, Gray et al. (2015) introduced
11 miRNAs signiﬁcantly up-regulated in response to hypoxic
conditions while miR-292 showed the highest variations in these
exosomes. Moreover, exosome proﬁling from cardiac ﬁbroblasts
was shown to be enriched with miR-21-3p (miR-21∗). These
ﬁbroblasts aﬀect cardiomyocytes and secrete the mediators
of cardiac hypertrophy (Bang et al., 2014). Knowing the
mechanisms underlying these communications and recognizing
potential strong biomarkers for diagnosis and treatment of CVDs
will help us in development of future molecular therapeutics.
miRNA Therapeutics in CVD
In the past decade, outstanding researches in the ﬁeld of
miRNA drugs have changed the face of molecular medicine.
miRNA-based therapeutics mainly focus on reinstating the
miRNA expression levels. Two main approaches include
overexpression of downregulated miRNAs and suppression of
overexpressed ones. These approaches have been subject to
diﬀerent modiﬁcations in order to improve the eﬃciency of
delivery and less oﬀ-target eﬀects. Promising tools in this regard
are the oligonucleotides that mimic the endogenous miRNA
or suppress the mature miRNA by sequence complementarity.
Addition of locked nucleic acids (LNAs) or 2′-O-methylation of
the antisense oligonucleotides increases the binding speciﬁcity
while cholesterol conjugation enhances the circulation time,
serum stability, and cellular uptake. Expression vectors bearing
the pre-miRNA sequences or tandem miRNA target sites
(sponges) sound promising for in vitro overexpression or
suppression of miRNAs, respectively. Another issue to overcome
is the eﬃcient delivery of each of the miRNA drugs. Naked
oligonucleotides are less eﬃcient due to their instability in
vitro or in vivo which subject them to diﬀerent nucleases.
Lipid-based vehicles, viral systems, and cationic polymers are
among the main delivery tools for miRNA-based therapeutics.
Each of these strategies has its own challenges and still
needs improvements to address problems such as cytotoxicity,
immunogenicity, and low eﬃciency (van Rooij and Olson,
2012). Fiedler et al. (2011) compared the eﬀect of diﬀerent
doses of cholesterol-based anti-miR-24 (antagomirs) on miR-
24 expression in cardiomyocytes and cardiac endothelial cells.
They showed a cell-type speciﬁc tendency or mechanism
for antagomir uptake by these tissues. Cholesterol-based
antagomirs for silencing miR-21 were also proved to inhibit
cardiac ﬁbrosis and dysfunction (Kumarswamy et al., 2012).
van Rooij et al. (2008) used anti-miR-29b oligonucleotides
(cholesterol modiﬁed) after myocardial infarction and observed
upregulation of ECM proteins leading to cardiac ﬁbrosis.
Also, Bonauer et al. (2009) demonstrated that intravenous
injection of miR-92a antagomir, improved the function of
damaged tissue in models of myocardial infarction. Inhibition
of miR-92a results in neoangiogenic eﬀects and functional
recovery of ischemic tissues (Bonauer et al., 2009). Another
promising miRNA in CVD therapeutics is miR-208 which
is implicated in cardiac remodeling. LNA-modiﬁed anti-miR-
208 oligonucleotides have successfully prevented pathologically
associated cardiac remodeling during diastolic heart disease (van
Rooij et al., 2007). A common issue in these approaches is in
vivo instability and the low homing eﬃciency of oligonucleotides
which results in modest changes in the expression levels of the
target protein. Accordingly, improved stabilization or eﬃcient
delivery vehicles are required. Examples of such vehicles are
adeno-associated viruses (AAVs). AAV9, a speciﬁc serotype of
AAVs, has tropism for myocardiocytes and enriches in the heart
(Bish et al., 2008). In another study Santulli et al. (2014b).
proved that miR-126-3p down-regulation using an adeno-viral
vector containing miR-126-3p target sites inhibits proliferative
vascular smooth muscle cells and prevents restenosis in animal
models. miR-126 is an endothelial speciﬁc miRNA that regulates
vascular integrity and angiogenesis. These strategies provide an
eﬃcient tool for cardiac gene transfer and targeted delivery of
miRNA-based therapeutics.
Due to their natural role in miRNA secretion and shuttling
between diﬀerent cells, exosomes are of great interest in miRNA
therapeutics. Exosomes are ﬂexible in size and cargo type and
their non-synthetic nature potentiates them for more eﬃcient
and non-immunogenic delivery of cargo while they maintain
the cargo integrity and stability. Exosomal membranes contain
certain proteins which have binding aﬃnity to speciﬁc receptors
on the surface of recipient cells. So, they can selectively target cell
types of interest and manipulating their miRNA components – as
well as other molecular cargoes – will provide promising tools for
the future of personalized medicine. In CVD, exosomes can be
used as therapeutic agents, as protein delivery carriers or as gene
therapy devices. Mesenchymal stem cell- derived exosomes have
been investigated in the ﬁeld of cardiac regenerative medicine
especially in myocardial ischemia/reperfusion injuries (Lai et al.,
2010). Martinez et al. (2006) have demonstrated that exosomes
bearing diﬀerentiation signals can aﬀect neovascularization and
they are promising for treatment of angiogenic defects. Moreover,
several exosomal miRNAs are implicated in angiogenesis and
vascular repair. Zhang et al. (2010) showed that exosomes
enriched with pre-miR-150 enhance endothelial cell migration.
They transfected pre-miR-150/anti-miR-150 oligonucleotides to
the THP-1 cell line and collected the conditioned media of these
cells which was enriched with the exogenous oligonucleotides-
bearing exosomes (Zhang et al., 2010). This conditioned medium
aﬀects the migration ability of endothelial cells. Exosome are
novel promising elements for the future of CVD treatment due
to their targeted delivery capacity and their microenvironment-
dependent nature. The latter property triggers their activation
in relation to the pathological microenvironment such as pH
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or substrate concentration. However, further studies would
be necessary to overcome obstacles such as engineering and
purifying exosomes, cargo loading into them and optimizing
their quality and characterization for targeted delivery.
Conclusion
Cardiovascular diseases are the one of the leading causes of
death worldwide. Most of CVDs can be prevented by controlling
behavioral and environmental risk factors and early diagnosis and
management play an important role in this regard. In this review,
we focused on miRNAs as small non-coding RNAs involved in
a variety of key cellular processes. Several miRNA biomarkers
have been introduced for diﬀerent CV situations. miRNAs have
emerged as attractive novel therapeutics and they have several
advantages over other molecular therapeutics due to their small
size, conserved sequences and their stability in the body ﬂuids.
First anti-cancer miRNA-based drug, MRX-34 (a liposome-
based miR-34 mimic) developed by Mirna Therapeutics came
to the clinic in 2013 for the treatment of hepatocellular
carcinoma (mirnarx.com; NCT01829971). Current achievements
have portrayed a promising future for miRNA-based therapeutics
although still several obstacles including their stability, renal
clearance, oﬀ-target eﬀects, ineﬃcient endocytosis by target
cells or the immunogenicity of delivery vehicles, need to be
overcome. In CVD, some miRNA-based strategies have resulted
in promising ﬁndings, including anti-miR-126 approaches that
resulted in vascular smooth muscle cells and restenosis inhibition
(Santulli et al., 2014b). Also, novel methodologies such as
exosome-based delivery of miRNA drugs provide reliable
evidence to overcome impediments such as ineﬃcient, unspeciﬁc
delivery, and immunogenic reactions. But these drugs still need
investigations on diﬀerent aspects of miRNA biology, their long
term eﬀects, subsequent biochemical and oﬀ-target eﬀects and
miRNA pathway analysis.
Acknowledgment
NN is supported by a grant (#92002177) from Iran National
Research Foundation (INSF).
References
Adachi, T., Nakanishi, M., Otsuka, Y., Nishimura, K., Hirokawa, G., Goto, Y., et al.
(2010). Plasma microRNA 499 as a biomarker of acute myocardial infarction.
Clin. Chem. 56, 1183–1185. doi: 10.1373/clinchem.2010.144121
Bang, C., Batkai, S., Dangwal, S., Gupta, S., Foinquinos, A., Holzmann, A.,
et al. (2014). Cardiac ﬁbroblast–derived microRNA passenger strand-enriched
exosomes mediate cardiomyocyte hypertrophy. J. Clin. Invest. 124, 2136–2146.
doi: 10.1172/JCI70577
Bish, L., Morine, K., Sleeper, M., Sanmiguel, J., Wu, D., Gao, G., et al. (2008).
Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer
superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene
Ther. 19, 1359–1368. doi: 10.1089/hum.2008.123
Bonauer, A., Carmona, G., Iwasaki, M., Mione, M., Koyanagi, M., Fischer, A.,
et al. (2009). MicroRNA-92a controls angiogenesis and functional recovery of
ischemic tissues in mice. Science 324, 1710–1713. doi: 10.1126/science.1174381
Bostjancic, E., Zidar, N., Stajer, D., and Glavac, D. (2010). MicroRNAs miR-1, miR-
133a, miR-133b and miR-208 are dysregulated in human myocardial infarction.
Cardiology 115, 163–169. doi: 10.1159/000268088
Calin, G., Dumitru, C., Shimizu, M., Bichi, R., Zupo, S., Noch, E., et al. (2002).
Frequent deletions and down-regulation of microRNA genes miR15 and miR16
at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 99,
15524–15529. doi: 10.1073/pnas.242606799
Charan Reddy, K. (2014). Regulatory noncoding RNAs in cardiovascular disease:
shedding light on ‘Dark Matter.’ J. Cardiovasc. Dis. 3, 1–7.
Cheng, Y., Tan, N., Yang, J., Liu, X., Cao, X., He, P., et al. (2010). A translational
study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin.
Sci. (Lond.) 119, 87–95. doi: 10.1042/CS20090645
Corsten, M., Dennert, R., Jochems, S., Kuznetsova, T., Devaux, Y., Hofstra, L., et al.
(2010). Circulating MicroRNA-208b and MicroRNA-499 reﬂect myocardial
damage in cardiovascular disease. Circ. Cardiovasc. Genet. 3, 499–506. doi:
10.1161/CIRCGENETICS.110.957415
Devaux, Y., Mueller, M., Haaf, P., Goretti, E., Twerenbold, R., Zangrando, J., et al.
(2015). Diagnostic and prognostic value of circulating microRNAs in patients
with acute chest pain. J. Intern. Med. 277, 260–271. doi: 10.1111/joim.12183
Devaux, Y., Vausort, M., Mccann, G., Kelly, D., Collignon, O., Ng, L., et al.
(2013). A panel of 4 microRNAs facilitates the prediction of left ventricular
contractility after acute myocardial infarction. PLoS ONE 8:e70644. doi:
10.1371/journal.pone.0070644
Duisters, R., Tijsen, A., Schroen, B., Leenders, J., Lentink, V., Van Der Made, I.,
et al. (2009). miR-133 and miR-30 regulate connective tissue growth factor:
implications for a role of microRNAs in myocardial matrix remodeling. Circ.
Res. 104, 170–178. doi: 10.1161/CIRCRESAHA.108.182535
Eiring, A., Harb, J., Neviani, P., Garton, C., Oaks, J., Spizzo, R., et al. (2010). miR-
328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA
translation in leukemic blasts. Cell 140, 652–665. doi: 10.1016/j.cell.2010.
01.007
Fabbri, M., Paone, A., Calore, F., Galli, R., Gaudio, E., Santhanam, R., et al. (2012).
MicroRNAs bind to Toll-like receptors to induce prometastatic inﬂammatory
response. PNAS 109, E2110–E2116. doi: 10.1073/pnas.1209414109
Fichtlscherer, S., De Rosa, S., Fox, H., Schwietz, T., Fischer, A., Liebetrau, C., et al.
(2010). Circulating microRNAs in patients with coronary artery disease. Circ.
Res. 107, 677–684. doi: 10.1161/CIRCRESAHA.109.215566
Fiedler, J., Jazbutyte, V., Kirchmaier, B., Gupta, S., Lorenzen, J., Hartmann, D.,
et al. (2011). MicroRNA-24 regulates vascularity after myocardial infarction.
Circulation 124, 720–730. doi: 10.1161/CIRCULATIONAHA.111.039008
Fukushima, Y., Nakanishi, M., Nonogi, H., Goto, Y., and Iwai, N. (2011).
Assessment of plasma miRNAs in congestive heart failure. Circ. J. 75, 336–340.
doi: 10.1253/circj.CJ-10-0457
Gray,W., French, K., Ghosh-Choudhary, S., Maxwell, J., Brown, M., Platt, M., et al.
(2015). Identiﬁcation of therapeutic covariant microRNA clusters in hypoxia-
treated cardiac progenitor cell exosomes using systems biology. Circ. Res. 116,
255–263. doi: 10.1161/CIRCRESAHA.116.304360
Ha, M., and Kim, V. (2014). Regulation of microRNA biogenesis. Nat. Rev. Mol.
Cell Biol. 15, 509–524. doi: 10.1038/nrm3838
Icli, B., Wara, A., Moslehi, J., Sun, X., Plovie, E., Cahill, M., et al.
(2013). MicroRNA-26a regulates pathological and physiological angiogenesis
by targeting BMP/SMAD1 signaling. Circ. Res. 113, 1231–1241. doi:
10.1161/CIRCRESAHA.113.301780
Ji, X., Takahashi, R., Hiura, Y., Hirokawa, G., Fukushima, Y., and Iwai, N. (2009).
Plasma miR-208 as a biomarker of myocardial injury. Clin. Chem. 55, 1944–
1949. doi: 10.1373/clinchem.2009.125310
Kumarswamy, R., Volkmann, I., Jazbutyte, V., Dangwal, S., Park, D., and Thum, T.
(2012). Transforming growth factor-β-induced endothelial-to-mesenchymal
transition is partly mediated by microRNA-21. Arterioscler. Thromb. Vasc. Biol.
32, 361–369. doi: 10.1161/ATVBAHA.111.234286
Lai, R., Arslan, F., Lee, M., Sze, N., Choo, A., Chen, T., et al. (2010). Exosome
secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell
Res. 4, 214–222. doi: 10.1016/j.scr.2009.12.003
Lee, I., Ajay, S., Yook, J., Kim, H., Hong, S., Kim, N., et al. (2009). New class of
microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction
sites. Genome Res. 19, 1175–1183. doi: 10.1101/gr.089367.108
Frontiers in Genetics | www.frontiersin.org 5 June 2015 | Volume 6 | Article 232
Nouraee and Mowla miRNAs in cardiovascular diseases
Li, C., Fang, Z., Jiang, T., Zhang, Q., Liu, C., Zhang, C., et al. (2013). Serum
microRNAs proﬁle from genome-wide serves as a ﬁngerprint for diagnosis of
acute myocardial infarction and angina pectoris. BMCMed. Genomics 6:16. doi:
10.1186/1755-8794-6-16
Lin, S., and Gregory, R. (2015).MicroRNA biogenesis pathways in cancer.Nat. Rev.
Cancer 15, 321–333. doi: 10.1038/nrc3932
Lu, J., Getz, G., Miska, E., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005).
MicroRNA expression proﬁles classify human cancers. Nature 435, 834–838.
doi: 10.1038/nature03702
Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang, F., et al. (2010). MicroRNA-
328 contributes to adverse electrical remodeling in atrial ﬁbrillation. Circulation
122, 2378–2387. doi: 10.1161/CIRCULATIONAHA.110.958967
Martinez, M., Larbret, F., Zobairi, F., Coulombe, J., Debili, N., Vainchenker, W.,
et al. (2006). Transfer of diﬀerentiation signal by membrane microvesicles
harboring hedgehog morphogens. Blood 108, 3012–3020. doi: 10.1182/blood-
2006-04-019109
Melo, S., Sugimoto, H., O’connell, J., Kato, N., Villanueva, A., Vidal, A.,
et al. (2014). Cancer exosomes perform cell-independent microRNA
biogenesis and promote tumorigenesis. Cancer Cell 26, 707–721. doi:
10.1016/j.ccell.2014.09.005
Mendis, S., Puska, P., and Norrving, B. (eds). (2011). Global Atlas on
Cardiovascular Disease Prevention and Control. Geneva: World Health
Organization in collaboration with the World Heart Federation and the World
Stroke Organization.
Montecalvo, A., Larregina, A., Shufesky, W., Stolz, D., Sullivan, M., Karlsson, J.,
et al. (2012). Mechanism of transfer of functional microRNAs between mouse
dendritic cells via exosomes. Blood 119, 756–766. doi: 10.1182/blood-2011-02-
338004
Pegtel, D., Cosmopoulos, K., Thorley-Lawson, D., Van Eijndhoven, M.,
Hopmans, E., Lindenberg, J., et al. (2010). Functional delivery of viral
miRNAs via exosomes. Proc. Natl. Acad. Sci. U.S.A. 107, 6328–6333. doi:
10.1073/pnas.0914843107
Ren, J., Zhang, J., Xu, N., Han, G., Geng, Q., Song, J., et al. (2013). Signature of
circulating microRNAs as potential biomarkers in vulnerable coronary artery
disease. PLoS ONE 8:e80738. doi: 10.1371/journal.pone.0080738
Sahoo, S., and Losordo, D. (2014). Exosomes and cardiac repair after myocardial
infarction. Circ. Res. 114, 333–344. doi: 10.1161/CIRCRESAHA.114.300639
Salmena, L., Poliseno, L., Tay, Y., Kats, L., and Pandolﬁ, P. (2011). A ceRNA
hypothesis: the rosetta stone of a hidden rna language. Cell 146, 353–358. doi:
10.1016/j.cell.2011.07.014
Santulli, G. (2013). Epidemiology of cardiovascular disease in the 21st century:
updated numbers and updated facts. J. Cardiovasc. Dis. 1, 1–2.
Santulli, G., Iaccarino, G., De Luca, N., Trimarco, B., and Condorelli, G.
(2014a). Atrial ﬁbrillation and microRNAs. Front. Physiol. 5:15. doi:
10.3389/fphys.2014.00015
Santulli, G., Wronska, A., Uryu, K., Diacovo, T., Gao, M., Marx, S., et al. (2014b).
A selective microRNA-based strategy inhibits restenosis while preserving
endothelial function. J. Clin. Invest. 124, 4102–4114. doi: 10.1172/JCI76069
Sardu, C., Marfella, R., Santulli, G., and Paolisso, G. (2014). Functional role of
miRNA in cardiac resynchronization therapy. Pharmacogenomics 15, 1159–
1168. doi: 10.2217/pgs.14.76
Stoorvogel, W. (2012). Functional transfer of microRNA by exosomes. Blood 119,
646–648. doi: 10.1182/blood-2011-11-389478
Tay, Y., Zhang, J., Thomson, A., Lim, B., and Rigoutsos, I. (2008). MicroRNAs
to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell
diﬀerentiation. Nature 455, 1124–1128. doi: 10.1038/nature07299
Terentyev, D., Belevych, A., Terentyeva, R., Martin, M., Malana, G., Kuhn, D., et al.
(2009). miR-1 overexpression enhances Ca(2+) release and promotes cardiac
arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing
CaMKII-dependent hyperphosphorylation of RyR2. Circ. Res. 104, 514–521.
doi: 10.1161/CIRCRESAHA.108.181651
Thum, T., Catalucci, D., and Bauersachs, J. (2008a). MicroRNAs: novel regulators
in cardiac development and disease. Cardiovasc. Res. 79, 562–570. doi:
10.1093/cvr/cvn137
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., et al. (2008b).
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase
signalling in ﬁbroblasts. Nature 456, 980–984. doi: 10.1038/nature07511
Tijsen, A., Creemers, E., Moerland, P., De Windt, L., Van Der Wal, A., Kok, W.,
et al. (2010). MiR423-5p as a circulating biomarker for heart failure. Circ. Res.
106, 1035–1039. doi: 10.1161/CIRCRESAHA.110.218297
van Rooij, E., and Olson, E. (2009). Searching for MiR-acles in Cardiac Fibrosis.
Circ. Res. 104, 138–140. doi: 10.1161/CIRCRESAHA.108.192492
van Rooij, E., and Olson, E. (2012). MicroRNA therapeutics for cardiovascular
disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11, 860–872. doi:
10.1038/nrd3864
van Rooij, E., Sutherland, L., Liu, N., Williams, A., Mcanally, J., Gerard, R.,
et al. (2006). A signature pattern of stress-responsive microRNAs that can
evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U.S.A. 103,
18255–18260. doi: 10.1073/pnas.0608791103
van Rooij, E., Sutherland, L., Qi, X., Richardson, J., Hill, J., and Olson, E.
(2007). Control of stress-dependent cardiac growth and gene expression by a
microRNA. Science 316, 575–579. doi: 10.1126/science.1139089
van Rooij, E., Sutherland, L., Thatcher, J., Dimaio, J., Naseem, R.,Marshall,W., et al.
(2008). Dysregulation of microRNAs after myocardial infarction reveals a role
of miR-29 in cardiac ﬁbrosis. Proc. Natl. Acad. Sci. U.S.A. 105, 13027–13032.
doi: 10.1073/pnas.0805038105
Wang, F., Long, G., Zhao, C., Li, H., Chaugai, S., Wang, Y., et al. (2013). Plasma
microRNA-133a is a new marker for both acute myocardial infarction and
underlying coronary artery stenosis. J. Trans. Med. 11, 222. doi: 10.1186/1479-
5876-11-222
Wang, G., Zhu, J., Zhang, J., Li, Q., Li, Y., He, J., et al. (2010). Circulating
microRNA: a novel potential biomarker for early diagnosis of acute myocardial
infarction in humans. Eur. Heart J. 31, 659–666. doi: 10.1093/eurheartj/
ehq013
Widera, C., Gupta, S., Lorenzen, J., Bang, C., Bauersachs, J., Bethmann, K.,
et al. (2011). Diagnostic and prognostic impact of six circulating microRNAs
in acute coronary syndrome. J. Mol. Cell Cardiol. 51, 872–875. doi:
10.1016/j.yjmcc.2011.07.011
Wronska, A., Kurkowska-Jastrzebska, I., and Santulli, G. (2015). Application of
microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol.
(Oxf.) 213, 60–83. doi: 10.1111/apha.12416
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., et al. (2007). The muscle-speciﬁc
microRNAmiR-1 regulates cardiac arrhythmogenic potential by targeting GJA1
and KCNJ2. Nat. Med. 13, 486–891. doi: 10.1038/nm1569
Yang, M., Chen, J., Su, F., Yu, B., Su, F., Lin, L., et al. (2011). Microvesicles secreted
by macrophages shuttle invasion-potentiating microRNAs into breast cancer
cells.Mol. Cancer 10, 117. doi: 10.1186/1476-4598-10-117
Yoo, A., Sun, A., Li, L., Shcheglovitov, A., Portmann, T., Li, Y., et al. (2011).
MicroRNA-mediated conversion of human ﬁbroblasts to neurons. Nature 476,
228–231. doi: 10.1038/nature10323
Zampetaki, A., Willeit, P., Tilling, L., Drozdov, I., Prokopi, M., Renard, J., et al.
(2012). Prospective study on circulating MicroRNAs and risk of myocardial
infarction. J. Am. Coll. Cardiol. 60, 290–294. doi: 10.1016/j.jacc.2012.
03.056
Zhang, Y., Liu, D., Chen, X., Li, J., Li, L., Bian, Z., et al. (2010). Secreted monocytic
miR-150 enhances targeted endothelial cell migration. Mol. Cell 39, 133–144.
doi: 10.1016/j.molcel.2010.06.010
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Nouraee and Mowla. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Genetics | www.frontiersin.org 6 June 2015 | Volume 6 | Article 232
